Sadek S A, Cranford C, Eriksen C, Walker M, Campbell C, Baker P R, Wood R A, Cuschieri A
Department of Surgery, Ninewells Hospital and Medical School, University of Dundee, Scotland.
Aliment Pharmacol Ther. 1988 Feb;2(1):47-54. doi: 10.1111/j.1365-2036.1988.tb00671.x.
In a double-blind placebo-controlled trial of patients undergoing elective abdominal surgery (n = 91), a single intravenous infusion of ceruletide (2.5 ng kg-1 min-1 for 1 hour) resulted in audible bowel sounds in 42/47 patients as opposed to 30/44 receiving placebo (P less than 0.025). Excessive bowel sounds were noted in 16 patients in the ceruletide group and four receiving placebo (P less than 0.01). Significantly more patients (P less than 0.01) in the ceruletide group (22/45 versus 9/44) passed flatus per rectum between the second and third post-operative day. Ceruletide infusion was accompanied by a significant increase in the incidence of nausea and vomiting (P less than 0.005, P less than 0.0025) but these side effects were short-lived. These results indicate that ceruletide is likely to be a useful therapeutic agent for acute intestinal adynamic motility disorders.
在一项针对择期腹部手术患者（n = 91）的双盲安慰剂对照试验中，单次静脉输注蛙皮素（2.5纳克/千克/分钟，持续1小时）后，47例患者中有42例出现可闻及的肠鸣音，而接受安慰剂的44例患者中只有30例出现（P < 0.025）。蛙皮素组有16例患者出现肠鸣音亢进，接受安慰剂组有4例（P < 0.01）。在术后第二天至第三天期间，蛙皮素组经直肠排气的患者明显更多（P < 0.01）（45例中有22例，而接受安慰剂组44例中有9例）。输注蛙皮素后恶心和呕吐的发生率显著增加（P < 0.005，P < 0.0025），但这些副作用是短暂的。这些结果表明，蛙皮素可能是治疗急性肠道动力障碍的一种有用药物。
